Clinical Trials Logo

Risk Factors for IPA clinical trials

View clinical trials related to Risk Factors for IPA.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01866020 Completed - Survival After IPA Clinical Trials

Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Critically Ill Patients

DipA
Start date: January 2013
Phase: N/A
Study type: Observational

Invasive pulmonary aspergillosis (IPA) is difficult to diagnose and remains a cause of high morbidity and mortality in critically ill patients in the ICU. Accepted diagnostic protocols for haemato-oncological patients are not applicable for critically ill patients in ICUs. Definitive discrimination between aspergillic colonisation and IPA often depends on the clinical experience of the treating physician, evaluating clinical signs, co-morbidities, and course of the disease. Life saving treatment with the first line antimycotic Voriconazol (Vfend®) can only be initiated after diagnosis of IPA. In this prospective clinical trial the investigators aim to structure, optimize and fast track the diagnostic pathway of IPA in critically ill patients treated in our ICU-department.